Compare Paycom Software Inc (PAYC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Paycom Software Inc trades at $238.6 (market cap $10.67B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.63% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PAYC | SYRE | |
|---|---|---|
Market Cap | $10.67B | $7.52B |
Volume | 411,289 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $240.52 | $108.92 |
52-Week Low | $113.59 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $11.45B | $6.52B |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAYC trades at $239.00, up 1.7% today, with a bullish technical trend and strong fundamentals. The company reported Q2 2026 EPS of $2.78, beating estimates by 17%, and raised full-year guidance to 7-8% revenue growth. Valuation metrics show a P/E of 25.04 and robust profitability with a net margin of 22.78%. Recent news highlights institutional buying and positive earnings momentum.
The outlook is positive given earnings beats and raised guidance, but risks include high valuation multiples and competitive pressures. Analysts are mixed with a $211.08 consensus target, below the current price, suggesting cautious optimism. The stock's proximity to its 52-week high warrants monitoring for pullbacks.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
